Dermatology
Antisense oligonucleotides make sense for treating psoriasis
Published in Gene Therapy Weekly, February 26th, 2004
According to a study from Australia, "antisense oligonucleotides are emerging as an exciting therapeutic strategy for treating skin diseases such as psoriasis. Potential antisense targets are proteins upregulated in psoriatic skin, in particular those associated with inflammation (intercellular adhesion molecule (ICAM)-1, interleukin (IL)-2 and -8), proliferation (insulin-like growth factor type I receptor (IGF-IR), epidermal growth factor (EGF)) and hyperangiogenesis (vascular endothelial growth factor (VEGF)). Whereas topical application and subsequent penetration of large oligonucleodies into normal skin...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-02-26)
More Articles from Gene Therapy Weekly
- Drug Resistance
Restored caspase expression may resensitize lung cancer cells to chemotherapy - Cancer Therapy
Truncated growth factor signals staunch pancreatic cancer cell proliferation - Clinical Trials
Company wins MEDC contract for dendrimer technology - Coxsackie Virus
Report addresses efficacy of Ampligen in treating myocarditis virus - Drug Delivery
A novel polymeric carrier ushers biomolecular drugs to their targets - Enzymology
Escherichia coli purine nucleoside phosphorylase strengthens gene therapy - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
